- Home
- MNPR vs SES Comparison
MNPR vs SES Comparison
Compare MNPR & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- SES
- Stock Information
- Founded
- MNPR 2014
- SES 2012
- Country
- MNPR United States
- SES United States
- Employees
- MNPR N/A
- SES N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- SES Auto Parts:O.E.M.
- Sector
- MNPR Health Care
- SES Consumer Discretionary
- Exchange
- MNPR Nasdaq
- SES Nasdaq
- Market Cap
- MNPR 249.5M
- SES 226.6M
- IPO Year
- MNPR 2019
- SES N/A
- Fundamental
- Price
- MNPR $31.73
- SES $0.91
- Analyst Decision
- MNPR Strong Buy
- SES Hold
- Analyst Count
- MNPR 5
- SES 3
- Target Price
- MNPR $59.50
- SES $1.50
- AVG Volume (30 Days)
- MNPR 18.2K
- SES 12.4M
- Earning Date
- MNPR 05-13-2025
- SES 04-24-2025
- Dividend Yield
- MNPR N/A
- SES N/A
- EPS Growth
- MNPR N/A
- SES N/A
- EPS
- MNPR N/A
- SES N/A
- Revenue
- MNPR N/A
- SES $7,833,000.00
- Revenue This Year
- MNPR N/A
- SES $929.56
- Revenue Next Year
- MNPR N/A
- SES $140.44
- P/E Ratio
- MNPR N/A
- SES N/A
- Revenue Growth
- MNPR N/A
- SES N/A
- 52 Week Low
- MNPR $1.72
- SES $0.20
- 52 Week High
- MNPR $54.30
- SES $2.53
- Technical
- Relative Strength Index (RSI)
- MNPR 37.28
- SES 53.38
- Support Level
- MNPR $34.02
- SES $0.91
- Resistance Level
- MNPR $36.82
- SES $1.01
- Average True Range (ATR)
- MNPR 3.54
- SES 0.08
- MACD
- MNPR -0.71
- SES -0.01
- Stochastic Oscillator
- MNPR 27.91
- SES 40.71
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.